Legend Biotech Reports Strong 2025 CARVYKTI Sales Growth, Achieves Profitability, and Advances Pipeline Despite New Patent Lawsuit

summarizeSummary

Legend Biotech reported strong 2025 financial results driven by significant CARVYKTI sales growth and achieved profitability for the product, despite an increased net loss due to foreign exchange fluctuations and new legal and safety challenges.

check_boxKey Events

• Strong CARVYKTI Sales Growth

  Collaboration revenue, primarily from CARVYKTI sales, surged to $944.8 million in 2025, a significant increase from $482.6 million in 2024, indicating robust commercial adoption.

• CARVYKTI Achieves Profitability

  CARVYKTI reached a profitable position by the end of 2025, triggering Janssen's right to recoup $319.1 million in funding advances and interest starting in 2026.

• Positive Clinical Data for CARVYKTI

  The Phase 3 CARTITUDE-4 clinical trial demonstrated significantly improved overall survival for CARVYKTI compared to standard care therapies, reinforcing its efficacy in earlier lines of multiple myeloma treatment.

• New Patent Infringement Lawsuit

  2seventy bio, Inc. filed a patent infringement complaint in the Unified Patent Court on January 5, 2026, alleging that CARVYKTI infringes its European patent, which the company intends to vigorously defend.

auto_awesomeAnalysis

Legend Biotech's 20-F filing reveals a pivotal year marked by substantial commercial success for its lead product, CARVYKTI, which nearly doubled collaboration revenue to $944.8 million in 2025 and achieved profitability. This strong performance is further bolstered by positive long-term overall survival data from the CARTITUDE-4 trial, reinforcing CARVYKTI's market position. However, the company faces significant challenges, including a new patent infringement lawsuit in Europe against CARVYKTI and recent FDA label updates for serious safety signals. While the overall net loss increased due to unrealized foreign exchange losses, the underlying operational performance and pipeline advancements, including progress on the Novartis licensing deal, indicate a robust growth trajectory. Investors should monitor the outcome of the patent litigation and the impact of safety label updates on CARVYKTI's commercialization, alongside continued pipeline development.